Journal of the National Comprehensive Cancer Network

Our medical research library holds 5 studies published in Journal of the National Comprehensive Cancer Network (2012–2018). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 4 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it. For 1 study PubMed has no abstract for, we give the abstract printed in the article or, where there is none, a summary we wrote from it, each labeled as such.

About the journal

• Publisher: Harborside Press
• Published: 2003 to the present, United States
• Language: English
• ISSN: 1540-1405 (print), 1540-1413 (electronic)
• Its record in the NLM Catalog

2010s

• Integrated Histogenetic Analysis Reveals BAP1-Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary. T. Bochtler, V. Endris, A. Reiling, et al. 2018;16(6):677-682. Case report PubMed · Publisher

  Abstract

  This case report presents a male patient with epithelioid mesothelioma that was initially misdiagnosed as cancer of unknown primary (CUP) and correctly identified using molecular panel sequencing. The patient had a prior history of colon and breast cancer. To assess the enlarged mediastinal lymph nodes, retrosternal lymphadenectomy was performed in 2016. The lymph nodes were histologically deemed unrelated to the known breast cancer by the reference pathologist, thus leading to the diagnosis of a CUP syndrome. When the patient presented to our center, targeted deep sequencing of both breast cancer and presumed CUP was performed to address the clonal relationship between both malignancies. A missense mutation in BAP1 was revealed in both samples, with coverage data indicating a germline event. The patient was subsequently counseled by a human geneticist and underwent genetic testing, which confirmed the germline nature of this mutation. Collectively, these data led to the diagnosis of BAP1 (BRCA1-associated protein-1) tumor predisposition syndrome (TPDS). With the knowledge of an underlying BAP1 mutation and its known frequent association with epithelioid mesothelioma, the histology was reassessed and the diagnosis was revised to epithelioid mesothelioma. At this point, peritoneal involvement of mesothelioma could be diagnosed and histologically confirmed. This case illustrates the potential of integrated histopathologic and molecular diagnostics in helping to decipher CUP syndromes and establish the correct diagnosis. Additionally, this case highlights typical features of BAP1 TPDS with its general susceptibility to cancers, with pleural and peritoneal mesotheliomas as most prevalent clinical entities and the typically more benign course of these epithelioid mesotheliomas compared with BAP1-unrelated cases of mesotheliomas.

  Copyright © 2018 by the National Comprehensive Cancer Network.

• NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. D.S. Ettinger, D.E. Wood, W. Akerley, et al. 2016;14(7):825-36. PubMed · Publisher · Free full text

  Abstract

  These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Malignant Pleural Mesothelioma (MPM). These NCCN Guidelines Insights discuss systemic therapy regimens and surgical controversies for MPM. The NCCN panel recommends cisplatin/pemetrexed (category 1) for patients with MPM. The NCCN panel also now recommends bevacizumab/cisplatin/pemetrexed as a first-line therapy option for patients with unresectable MPM who are candidates for bevacizumab. The complete version of the NCCN Guidelines for MPM, available at NCCN.org, addresses all aspects of management for MPM including diagnosis, evaluation, staging, treatment, surveillance, and therapy for recurrence and metastasis; NCCN Guidelines are intended to assist with clinical decision-making.

  Copyright © 2016 by the National Comprehensive Cancer Network.

• Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. K. Turner, S. Varghese, H.R. Alexander. 2012;10(1):49-57. Review PubMed · Publisher

  Abstract

  Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and ultimately fatal cancer that was first recognized and described a century ago. It is a diffuse primary malignant condition arising from the mesothelial lining of the peritoneum, and its natural history is hallmarked by a propensity to progress almost exclusively within the abdominal cavity throughout the entire course of disease. Patients afflicted with DMPM most commonly present with nonspecific abdominal symptoms that lead to diagnosis when the condition is relatively advanced. Historically, median overall survival for patients with DMPM without treatment is very short, averaging 6 months. Systemic chemotherapy using pemetrexed and cisplatin has an overall response rate of approximately 25% and a median overall survival of approximately 1 year. Many institutional reports have shown that in selected patients, operative cytoreduction and hyperthermic intraoperative peritoneal chemotherapy using cisplatin or mitomycin C is associated with long-term survival. Recent studies on the molecular biology of DMPM have yielded new insights relating to the potentially important role of the phosphatidylinositol 3-kinase/mammalian target of rapamycin and epidermal growth factor receptor pathways in this disease, which may translate into new therapeutic options for patients with DMPM.

• Malignant pleural mesothelioma. D.S. Ettinger, W. Akerley, H. Borghaei, et al. 2012;10(1):26-41. Guideline PubMed · Publisher

  Summary

  This article presented the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for malignant pleural mesothelioma (MPM). The guidelines were developed by the NCCN Non–Small Cell Lung Cancer panel in 2010 and were described as a consensus statement of the authors' views of currently accepted treatment approaches. The authors noted that mesothelioma occurs in approximately 2500 people in the United States each year, mainly in older men exposed to asbestos 20 to 40 years earlier, and that median overall survival is approximately 1 year. Screening for MPM was not recommended. For recurrent pleural effusion or pleural thickening, the recommended initial evaluation included chest CT with contrast, thoracentesis for cytology, and pleural biopsy, with thoracoscopic biopsy preferred. Management by an experienced multidisciplinary team was recommended. For medically operable patients with clinical stage I to III disease, trimodality therapy was recommended: chemotherapy, surgery by pleurectomy/decortication or extrapleural pneumonectomy, and radiotherapy. Chemotherapy alone was recommended for inoperable patients and for those with stage IV disease or sarcomatoid histology. Cisplatin plus pemetrexed (category 1) was described as the gold-standard first-line regimen; in a phase III trial it increased survival compared with cisplatin alone (12.1 vs. 9.3 months). Radiotherapy alone was not recommended. Radiotherapy could be used after extrapleural pneumonectomy, to prevent instrument-tract recurrence, and to relieve chest pain.

  PubMed has no abstract for this study, and the article doesn't print one. We wrote this summary from the full article with the help of AI. It is not the authors' wording.

• Novel therapies in phase II and III trials for malignant pleural mesothelioma. M.G. Zauderer, L.M. Krug. 2012;10(1):42-7. Review PubMed · Publisher · Free full text

  Abstract

  Mesothelioma is a rare malignancy of the pleura with limited therapeutic options. Despite the desperate need to develop better treatment for this disease, the rarity of the tumor type creates formidable challenges in clinical research. Nonetheless, several novel agents are under investigation. Most efforts are directed toward improving standard first-line therapy with pemetrexed and cisplatin, or developing effective second-line treatments. Several classes of drugs are being explored, including those that impact DNA transcription, cell-cycle progression, angiogenesis, and immune tolerance. This article describes several ongoing or recently completed phase II and III trials using novel agents vorinostat, everolimus, CBP501, MORAb-009, NGR-hTNF, WT1 vaccine, bevacizumab, cediranib, and thalidomide.

Browse every journal in the library or the library by type of article, or return to medical research.